Our data from the BALB/c mouse EAM model, which allows to study the transition from myocarditis to DCM phenotype16, showed for the first time that continued treatment with EP4 stimulant not only ameliorates cardiac malfunction with hemodynamic compromise during myocarditis, but also protects the heart affected by myocarditis from the development of DCM in association with the control of MMP-2 activation. Here, MMP2 is linked to familial dilated cardiomyopathy.